GSK and Janssen seek European approval for sirukumab in rheumatoid arthritis
GlaxoSmithKline (GSK) and Janssen-Cilag International have submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for the approval of sirukumab to treat moderately to severely active rheumatoid arthritis (RA) in adults.
Click on this link for more information.
